Halozyme Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Halozyme Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
3.7%
Buyback Yield
| Total Shareholder Yield | 3.7% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RV7's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RV7's dividend payments have been increasing.
Dividend Yield vs Market
| Halozyme Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RV7) | n/a |
| Market Bottom 25% (DE) | 1.7% |
| Market Top 25% (DE) | 4.8% |
| Industry Average (Biotechs) | 1.6% |
| Analyst forecast (RV7) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate RV7's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RV7's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RV7's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RV7 has not reported any payouts.